Healthcare Giant GlaxoSmithKline (NYSE:GSK) Bid on Human Genome Sciences- HGSI, GSK, HGSI, DNDN, ARNA, KERX, BPAX, VVUS, AEZS

Biotech drug maker Human Genome Sciences (NASDAQ:HGSI) has refused an unwanted $2.59 billion acquisition bid by GlaxoSmithKline (NYSE:GSK), the British pharmaceutical giant that spent almost 20 years helping the smaller firms bring its first drug to market.

Rockville, Md.-based Human Genome Sciences declared on Thursday the proposal underrates the firm and that it would explore other options, which could include a potential sale of the firm. It requested GlaxoSmithKline to contribute in its exploratory process.

Turning towards the investors who viewing HGSI against Dendreon Corporation (NASDAQ:DNDN) rose +11.69%, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) grew +5.09%, Keryx Biopharmaceuticals (NASDAQ:KERX) moved up +3.91%, Biosante Pharmaceuticals Inc (NASDAQ:BPAX) edged up +6.77%, VIVUS, Inc. (NASDAQ:VVUS) which also increased +0.23% and AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) surged +1.94%.

Human Genome Sciences (NASDAQ:HGSI) after opening at $14.20 hit high price of $14.61 and then closed at $14.17 by surging +97.63% and on last session volume of 126.54 million shares was surprisingly higher than its average volume of 5.82 million shares.

The stock price volatility was 3.81% for a week and 4.16% for a month as well as price volatility’s Average True Range for 14 days was 0.84 and its beta remained 3.83.

The liquidity measure in recent quarter results of the company was recorded 2.01 as current ratio and on the other side the debt to equity ratio was 1.78 and long-term debt to equity ratio also remained 1.35. The Company had total cash at hand $521.28 million and a book value per share as $2.30 in the most recent quarter.

HGSI generated revenue of 130.98 billion in the following twelve months and earned -$381.11 million. The Company showed a negative -290.98% in the net profit margin and as well as in its operating margin which remained -251.61%. Company’s annual sales growth for the past five year was 38.44%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.